HEALTH● LOWSep 30 · Sep 30, 2026, 10:04 AM
AbbVie's ABBV-295 delivers up to 9.8% weight loss in Phase 1
Seeking Alpha Tech · global
AbbVie's experimental drug ABBV-295 showed up to 9.8% weight loss in Phase 1 trials. This indicates a promising early development for a potential new medical treatment.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH54m agoThe health of Leo XIV: the Pope advances in his recovery, but uncertainty remains about his visit to South AmericaClarínHEALTH1h agoHealthcare workers protest in virtually every state over pay, shortages and staffingMexico News DailyHEALTH2h agoKFF: Individual health insurance enrollment fell 18 percent in JuneThe HillHEALTH2h agoPaxton suing Gerber and Nestlé over alleged arsenic and lead in baby foodThe Hill